CTLA4 and melanoma: The evidence of increased (≥1000/μL) absolute lymphocyte count (ALC) upon infusion of an immune checkpoint agent represented the first observation of clinical benefit in melanoma patients with advanced disease treated with anti-CTLA-4 mAb [12].